.jpeg "India, Russia Explore New Avenues in Pharma, Healthcare")
JP Nadda, Union Minister for Health & Family Welfare and Chemicals & Fertilizers, had a one-on-one discussion with H.E. Dmitry Nikolaevich Patrushev, Deputy Prime Minister of the Russian Federation, at Nirman Bhavan, New Delhi.
.jpeg "Fujifilm India Launches DR X-ray Facility to Boost Healthcare")
Fujifilm India has launched a digital radiology X-ray centre in the Community Health Centre (CHC) in Dholera, Gujarat
Wockhardt shares surged 7.45% to 1,435 following the publication of positive Phase 3 clinical trial results for its novel antibiotic Miqnaf (nafithromycin)
The results of a statewide review of 3.9 lakh lipid profile tests performed in the previous year have been made public by Metropolis Healthcare. According to the study, there has been a worrying change in the cardiovascular landscape of India
Global pharmaceutical giant Lupin Limited disclosed that its wholly owned subsidiary, Nanomi B.V., has executed a definitive agreement to acquire VISUfarma B.V., a specialty eye health company backed by GHO Capital Partners...
Syngene International has achieved a successful scale-up of the synthesis of a new active pharmaceutical ingredient for vascular calcification inhibition, progressing from lab-scale proof-of-concept to commercial-scale good manufacturing...
Moderna has conveyed that the primary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, the mRNA COVID-19 vaccine of their choice to the LP.8.1 variant of SARS-CoV-2, is in the positive range.
The revolutionary change that could dramatically impact the prevention of HIV may well hinge on how fast Indian regulators accept the proposal. Gilead Sciences, a US-based company, gave no-royalty licenses to four Indian firms
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) recently held a crucial meeting with the NICDC Logistics Data Services Limited (NLDSL) to launch Logistics e-Marketplace (LeMP) and a new under-development portal search engine regard
AbbVie announced that it has officially submitted a NDA to the USFDA for tavapadon, a next generation selective dopamine D1/D5 receptor partial agonist created to be taken once daily for oral administration for the treatment of Parkinson's...
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")